科華生物(002022.SZ):新型冠狀病毒突變核酸檢測試劑盒入圍出口“白名單”
格隆匯7月16日丨科華生物(002022.SZ)公佈,近日,公司獲悉,公司自主研發的新型冠狀病毒(2019-nCoV)突變核酸檢測試劑盒(熒光PCR法)入圍出口“白名單”。該試劑盒用於新型冠狀病毒(2019-nCoV)確診患者的咽拭子,鼻拭子和血漿中主要突變株(S基因突變包括N501Y、HV69-70del、K417N、E484K、K417T和D614G)的鑑別及相關流行病學監控。
此次公司檢測產品入圍出口“白名單”,有利於進一步提升公司新冠檢測產品的國際競爭力,拓展海外市場,將對公司業務發展具有正面影響。另一方面,隨着新冠疫情的發展逐步得到有效控制,新冠檢測產品需求的持續性存在一定的不確定性,同時,受檢測方法的選擇、境外市場推廣等多種因素的影響,產品銷售及利潤貢獻具有不確定性,公司目前尚無法預測上述產品對公司未來經營業績的具體影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.